Gilead Stock News

The antibiotics are prescribed to kill the chlamydia bacteria. Doxycycline or azithromycin is the preferred treatments. Azithromycin is taken in one dose. Although doxycycline costs less, it must be taken for seven days. chlamydia can be cured with the right

Kite Pharma, a Gilead Science Inc company (NASDAQ: GILD), churned out more data for its CAR-T Yescarta in first-line lymphoma patients.  The Company shared the data at the American Society of Hem

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced primary results from ZUMA-12, a global, multicenter, single-arm, open-label Phase 2 study evaluating Yescarta® (axicabtagene ciloleucel) as part of first-line treatment in patients with high-risk large B-cell lymphoma (LBCL). This is the first study to evaluate CAR T-cell therapy as part of first-line therapy in high-risk LBCL. The study is based on the desire to utilize potential curative treatment as

Westside Investment Management Inc. trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% during the third quarter, Holdings Channel reports. The fund owned 52,034 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. Gilead Sciences accounts for 1.8% of Westside Investment Management Inc.’s holdings, making the stock its 8th largest […]

Kite Pharma , a Gilead Science Inc''s Company (NASDAQ: GILD ), announced primary analysis results from the ZUMA-7 Phase 3 trial of Yescarta (axicabtagene ciloleucel) as a one-time infusion. The head-to-head study evaluated Yescarta against standard of care (SOC) for adults with large B-cell lymphoma (LBCL) who relapsed or were refractory to first-line treatment. With a median follow-up of over two years, the study met the primary endpoint of event-free survival. Yescarta demonstrated a 2.5 fold increase in alive patients at two years Full story available on Benzinga.com

Jaffetilchin Investment Partners LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 4,104 shares of the biopharmaceutical company’s stock, valued at approximately $287,000. Several other institutional investors also recently bought and sold shares of the company. Redwood Investment Management LLC boosted its […]

The global Antifungal Agents market was valued at 1116.22 Million USD in 2020 and will grow with a CAGR of 2.71% from 2020 to 2027. The report covers the key players of the industry including Company Profile, Product Specifications, Production

Kite Pharma, a Gilead Science Inc's Company (NASDAQ: GILD), announced primary analysis results from the ZUMA-7 Phase 3 trial of Yescarta (axicabtagene ciloleucel) as a one-time infusion. The head

Gilead Sciences, Inc. (NASDAQ:GILD) with the stream of -0.07% also noticed, India Eros STX Global Corporation (NYSE:ESGC) encountered a rapid change of 1.11% in the last hour of Fridays trading The post Project Future Performance Before Investment: Gilead Sciences, Inc. (NASDAQ:GILD), Eros STX Global Corporation (NYSE:ESGC) appeared first on Stocks Equity .

These stocks may suit the value investor Check out Joel Greenblatt Stock Picks » Download GuruFolio Report of Joel Greenblatt (Updated on 12/11/2021) Related Stocks: TSN , NRG , GILD ,

Janney Montgomery Scott LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 223,822 shares of the biopharmaceutical companys stock after selling 7,325 shares during the quarter. Janney Montgomery Scott LLCs []

Investors may want to consider the following non-cyclical stocks, as their earnings yields (as calculated via Joel Greenblatt (Trades, Portfolio)'s method) are outperforming the 20-year high quality m

TCW Group Inc. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 673,377 shares of the biopharmaceutical companys stock after selling 6,725 shares during the quarter. TCW Group []